stockrow
Saturday 7 November 2026
Export OGEN’s income statement to Excel — free account
Oragenics, Inc.
OGEN Healthcare Biotechnology
Oragenics, Inc.’s revenue for fiscal 2023 (year ended December 2023) was $37,700.00, down 71.3% from fiscal 2022.
- EPS
- +81.6%
- Free cash flow
- −66.4%
Quarter to June 2026, against a year earlier
0.35
0.00
0.00%
Follow OGEN
Alert me
Target Price Range
Analyst price targets
Free accountTen years at a glance Fiscal years to December
| Ten-year view | Analyst estimates Powerpack | |||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | TTM Jun ’26 | Trend | 10 yrs | 2026e | 2027e | 2028e | Next 3/yr |
| Income, $m | ||||||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | 0 | 0 | 0 | — | — | 0 | (34.2%) | — | — | — | — | |
| Gross margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 100.00 | 100.00 | 100.00 | — | — | 19.89 | +100.0 pt | ||||||
| EBT | (8) | (7) | (10) | (16) | (26) | (16) | (14) | (21) | (11) | (10) | (10) | +1.8% | ||||||
| EBT margin, % | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | (18,059.31) | (10,865.70) | (54,789.66) | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| Net income | (7) | (7) | (10) | (16) | (26) | (16) | (14) | (21) | (11) | (10) | (10) | +3.8% | ||||||
| Per share, $ | ||||||||||||||||||
| Per share, $ | Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 1.34 | 1.97 | 0.50 | 0.00 | 0.00 | 0.00 | n/m | |||||
| Earnings | (2,829.90) | (2,463.54) | (1,564.44) | (665.34) | (845.16) | (251.75) | (213.51) | (275.68) | (48.05) | (4.56) | (3.44) | (51.1%) | ||||||
| Cash flow | (2,830.04) | (2,357.00) | (1,243.81) | (553.74) | (539.90) | (208.19) | (227.63) | (97.34) | (38.90) | (4.29) | (2.30) | (51.4%) | ||||||
| Capex | (10.00) | 0.00 | (17.08) | (1.07) | 0.00 | (0.68) | (1.73) | (12.50) | 0.00 | 0.00 | 0.00 | n/m | ||||||
| Free cash flow | (2,840.04) | (2,357.00) | (1,260.89) | (554.81) | (539.90) | (208.87) | (229.36) | (109.84) | (38.90) | (4.29) | (2.30) | (51.4%) | ||||||
| Book value | 1,186.28 | 2,339.37 | 2,860.55 | 733.26 | 536.45 | 409.37 | 194.46 | 42.30 | (0.96) | 3.84 | 0.83 | (47.1%) | ||||||
| Shares, m | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 2 | 4 | +111.9% | ||||||
| Valuation, × | ||||||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | 0.00 | 0.00 | 0.00 | — | — | 0.00 | 0.0 | |||||
| P/S | — | — | — | — | — | 59.54 | 64.25 | 123.17 | — | — | 12.53 | 82.3 | ||||||
| P/B | — | — | — | — | — | 2.18 | 1.23 | 9.67 | — | — | 0.42 | 4.4 | ||||||
| EV/Sales | — | — | — | — | — | 31.03 | 22.94 | 114.41 | — | — | 0.69 | 56.1 | ||||||
| EV/FCF | — | — | — | — | — | (2.00) | (0.33) | (1.95) | — | — | (0.01) | (1.4) | ||||||
| Cash, $m | ||||||||||||||||||
| Cash, $m | Operating cash flow | (7) | (6) | (9) | (13) | (17) | (13) | (15) | (7) | (9) | (9) | (10) | +3.0% | |||||
| Capex | 0 | — | 0 | 0 | — | 0 | 0 | (1) | — | — | 0 | +67.8% | ||||||
| Free cash flow | (7) | (6) | (9) | (13) | (17) | (14) | (15) | (8) | (9) | (9) | (10) | +3.0% | ||||||
| Balance, $m | ||||||||||||||||||
| Balance, $m | Working capital | 3 | 6 | 21 | 17 | 17 | 26 | 13 | 2 | 0 | 8 | 4 | +12.5% | |||||
| Net debt | (4) | (6) | (20) | (18) | (18) | (27) | (11) | (3) | (1) | (8) | (4) | +8.4% | ||||||
| Shareholders’ equity | 3 | 6 | 21 | 17 | 17 | 26 | 13 | 3 | 0 | 8 | 4 | +12.1% | ||||||
| Returns, % | ||||||||||||||||||
| Returns, % | ROA | (168.47) | (116.83) | (77.41) | (74.47) | (137.54) | (66.98) | (66.47) | (209.44) | (328.26) | (170.58) | (264.23) | (2.1) pt | |||||
| ROIC | 0.00 | (2,795.56) | (927.17) | 0.00 | 0.00 | 0.00 | (569.54) | 0.00 | 0.00 | 0.00 | 0.00 | 0.0 pt | ||||||
| ROE | (220.80) | (452.93) | (153.18) | (122.09) | (259.28) | (93.80) | (81.08) | (317.98) | (1,550.11) | (243.94) | (1,307.07) | (23.1) pt | ||||||
| People | ||||||||||||||||||
| People | Employees | 15 | 6 | 6 | 7 | 7 | 5 | 6 | 5 | 5 | 6 | — | (9.7%) | |||||
| Revenue/emp, $m | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.02 | 0.02 | 0.01 | 0.00 | 0.00 | — | n/m | ||||||
Negative figures in brackets.
estimates
Fiscal years to Dec 2023 · latest quarter Sep 2023 · fundamentals updated 26 Oct 2026
Oragenics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| GNPX GENPREX | $1.7M | — (loss-making) | — | — | n/m | −32.98% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| PPCB Propanc Biopharma Inc | $1.7M | — (loss-making) | — | — | −99.64% (below 0%: shrinking) | −1,637.42% (below 0%: shrinking) | — | 0.00% | Compare |
| XRTX XORTX Therapeutics Inc. | $1.7M | — (loss-making) | — | — | n/m | −318.40% (below 0%: shrinking) | 0.00% | 0.00% | Compare |
| GOVX GeoVax Labs Inc. | $1.6M | — (loss-making) | — (loss-making) | +183.44% (above 0%: growing) | n/m | +15.81% (above 0%: growing) | 100.00% | 0.00% | Compare |
| ITRMF Iterum Therapeutics PLC | $1.6M | — (loss-making) | — (loss-making) | +110.81% (above 0%: growing) | n/m | −179.15% (below 0%: shrinking) | 94.87% | (1,982.31%) | Compare |
| OGEN Oragenics, Inc. | $1.6M | — (loss-making) | — (loss-making) | −75.33% (below 0%: shrinking) | n/m | −66.37% (below 0%: shrinking) | 100.00% | 0.00% | |
| VRAX Virax Biolabs Group Limited | $1.6M | — (loss-making) | — (loss-making) | — | −855.56% (below 0%: shrinking) | +32.24% (above 0%: growing) | (53.57%) | 0.00% | Compare |
| KAPA Kairos Pharma, Ltd. | $1.5M | — (loss-making) | — | — | n/m | −25.71% (below 0%: shrinking) | — | 0.00% | Compare |
| CARM Carisma Therapeutics Inc. | $1.5M | — (loss-making) | — (loss-making) | +392.01% (above 0%: growing) | n/m | +114.65% (above 0%: growing) | 100.00% | 96.83% | Compare |
| Median of peers | $1.6M | — | — | +183.44% | — | −29.34% | 47.44% | 0.00% |
Pay and ownership Proxy statement filed 20 May 2026
Chief executive’s pay
| Year | Total pay | Actually paid | $100 invested |
|---|---|---|---|
| 2025 | 609.16k | 407.46k | 0.66 |
| 2024 | 745.07k | 279.70k | (18.00) |
Ownership
Directors and executive officers, together
16.10%
Sabby Volatility Warrant Master Fund, Ltd.
9.60%
Total pay is as the Summary Compensation Table states it; actually paid revalues the year’s share awards
at its end, as the SEC’s pay-versus-performance rule asks. $100 invested is what $100 in the company’s
shares at the start of the earliest year shown was worth at each year’s end.
Ownership is the proxy’s own table: the directors and officers as a group, and every holder of 5% or more.
Read the proxy statement